GCGR and obesity due to melanocortin 4 receptor deficiency: Hence, bioactive peptidescotargeting GCGR and GLP-1R may remediate the blood glucose and fattyacid metabolism imbalance, tackling both diabetes and obesity to supersedecurrent monoagonist therapy.